TY - JOUR
T1 - Human Colon Tumors Express a Dominant-Negative Form of SIGIRR That Promotes Inflammation and Colitis-Associated Colon Cancer in Mice
AU - Zhao, Junjie
AU - Bulek, Katarzyna
AU - Gulen, Muhammet F.
AU - Zepp, Jarod A.
AU - Karagkounis, Georgio
AU - Martin, Bradley N.
AU - Zhou, Hao
AU - Yu, Minjia
AU - Liu, Xiuli
AU - Huang, Emina
AU - Fox, Paul L.
AU - Kalady, Matthew F.
AU - Markowitz, Sanford D.
AU - Li, Xiaoxia
N1 - Funding Information:
The authors thank Drs Somasekar Seshagiri and Steffen Durinck, Department of Molecular Biology, Genentech, for providing RNA sequencing data and preliminary analysis; Drs Laura Nagy and Sanjoy Roychowdhury in the Pathobiology Department of Cleveland Clinic Lerner Research Institute for their assistance in immunohistochemistry. Junjie Zhao and Jarod A. Zepp are supported by the Howard Hughes Med into Grad Initiative through the Molecular Medicine PhD Program at Cleveland Clinic Lerner College of Medicine, Case Western Reserve University.
Funding Information:
Funding This study was supported by National Institutes of Health grants P01 CA062220 (X. Li) and P50CA150964 (S.D.M.).
Funding Information:
The authors thank Drs Somasekar Seshagiri and Steffen Durinck, Department of Molecular Biology, Genentech, for providing RNA sequencing data and preliminary analysis; Drs Laura Nagy and Sanjoy Roychowdhury in the Pathobiology Department of Cleveland Clinic Lerner Research Institute for their assistance in immunohistochemistry. Junjie Zhao and Jarod A. Zepp are supported by the Howard Hughes Med into Grad Initiative through the Molecular Medicine PhD Program at Cleveland Clinic Lerner College of Medicine, Case Western Reserve University. This study was supported by National Institutes of Health grants P01 CA062220 (X. Li) and P50CA150964 (S.D.M.).
Publisher Copyright:
© 2015 AGA Institute.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Background & Aims Single immunoglobulin and toll-interleukin 1 receptor (SIGIRR), a negative regulator of the Toll-like and interleukin-1 receptor (IL-1R) signaling pathways, controls intestinal inflammation and suppresses colon tumorigenesis in mice. However, the importance of SIGIRR in human colorectal cancer development has not been determined. We investigated the role of SIGIRR in development of human colorectal cancer. Methods We performed RNA sequence analyses of pairs of colon tumor and nontumor tissues, each collected from 68 patients. Immunoblot and immunofluorescence analyses were used to determine levels of SIGIRR protein in primary human colonic epithelial cells, tumor tissues, and colon cancer cell lines. We expressed SIGIRR and mutant forms of the protein in Vaco cell lines. We created and analyzed mice that expressed full-length (control) or a mutant form of Sigirr (encoding SIGIRRN86/102S, which is not glycosylated) specifically in the intestinal epithelium. Some mice were given azoxymethane (AOM) and dextran sulfate sodium to induce colitis-associated cancer. Intestinal tissues were collected and analyzed by immunohistochemical and gene expression profile analyses. Results RNA sequence analyses revealed increased expression of a SIGIRR mRNA isoform, SIGIRRΔE8, in colorectal cancer tissues compared to paired nontumor tissues. SIGIRRΔE8 is not modified by complex glycans and is therefore retained in the cytoplasm - it cannot localize to the cell membrane or reduce IL1R signaling. SIGIRRΔE8 interacts with and has a dominant-negative effect on SIGIRR, reducing its glycosylation, localization to the cell surface, and function. Most SIGIRR detected in human colon cancer tissues was cytoplasmic, whereas in nontumor tissues it was found at the cell membrane. Mice that expressed SIGIRRN86/102S developed more inflammation and formed larger tumors after administration of azoxymethane and dextran sulfate sodium than control mice; colon tissues from these mutant mice expressed higher levels of the inflammatory cytokines IL-17A and IL-6 had activation of the transcription factors STAT3 and NFκB. SIGIRRN86/102S expressed in colons of mice did not localize to the epithelial cell surface. Conclusion Levels of SIGIRR are lower in human colorectal tumors, compared with nontumor tissues; tumors contain the dominant-negative isoform SIGIRRΔE8. This mutant protein blocks localization of full-length SIGIRR to the surface of colon epithelial cells and its ability to downregulate IL1R signaling. Expression of SIGIRRN86/102S in the colonic epithelium of mice increases expression of inflammatory cytokines and formation and size of colitis-associated tumors.
AB - Background & Aims Single immunoglobulin and toll-interleukin 1 receptor (SIGIRR), a negative regulator of the Toll-like and interleukin-1 receptor (IL-1R) signaling pathways, controls intestinal inflammation and suppresses colon tumorigenesis in mice. However, the importance of SIGIRR in human colorectal cancer development has not been determined. We investigated the role of SIGIRR in development of human colorectal cancer. Methods We performed RNA sequence analyses of pairs of colon tumor and nontumor tissues, each collected from 68 patients. Immunoblot and immunofluorescence analyses were used to determine levels of SIGIRR protein in primary human colonic epithelial cells, tumor tissues, and colon cancer cell lines. We expressed SIGIRR and mutant forms of the protein in Vaco cell lines. We created and analyzed mice that expressed full-length (control) or a mutant form of Sigirr (encoding SIGIRRN86/102S, which is not glycosylated) specifically in the intestinal epithelium. Some mice were given azoxymethane (AOM) and dextran sulfate sodium to induce colitis-associated cancer. Intestinal tissues were collected and analyzed by immunohistochemical and gene expression profile analyses. Results RNA sequence analyses revealed increased expression of a SIGIRR mRNA isoform, SIGIRRΔE8, in colorectal cancer tissues compared to paired nontumor tissues. SIGIRRΔE8 is not modified by complex glycans and is therefore retained in the cytoplasm - it cannot localize to the cell membrane or reduce IL1R signaling. SIGIRRΔE8 interacts with and has a dominant-negative effect on SIGIRR, reducing its glycosylation, localization to the cell surface, and function. Most SIGIRR detected in human colon cancer tissues was cytoplasmic, whereas in nontumor tissues it was found at the cell membrane. Mice that expressed SIGIRRN86/102S developed more inflammation and formed larger tumors after administration of azoxymethane and dextran sulfate sodium than control mice; colon tissues from these mutant mice expressed higher levels of the inflammatory cytokines IL-17A and IL-6 had activation of the transcription factors STAT3 and NFκB. SIGIRRN86/102S expressed in colons of mice did not localize to the epithelial cell surface. Conclusion Levels of SIGIRR are lower in human colorectal tumors, compared with nontumor tissues; tumors contain the dominant-negative isoform SIGIRRΔE8. This mutant protein blocks localization of full-length SIGIRR to the surface of colon epithelial cells and its ability to downregulate IL1R signaling. Expression of SIGIRRN86/102S in the colonic epithelium of mice increases expression of inflammatory cytokines and formation and size of colitis-associated tumors.
KW - Colorectal Cancer
KW - TLR-IL-1R
KW - Tumor Suppressor
UR - http://www.scopus.com/inward/record.url?scp=84952889382&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2015.08.051
DO - 10.1053/j.gastro.2015.08.051
M3 - Article
C2 - 26344057
AN - SCOPUS:84952889382
VL - 149
SP - 1860-1871.e8
JO - Gastroenterology
JF - Gastroenterology
SN - 0016-5085
IS - 7
ER -